SETD2 and neoplasm: For example, mutatedPBRM1 was included in a composite biomarker together with tumor infiltrating lymphocytes (TILs) and absence of necrosis predicting a favorable response to ICIs.24,25 Likewise,SETD2 loss results in greater vulnerability to immune checkpoint blockade compared to SETD2-proficient tumors,in vitro andin vivo.